Study #1: A Research Study on Treatment of Marijuana Use and Schizophrenia

Researchers at the Psychotic Disorders Research Program in the Department of Psychiatry at UMass Medical School in Worcester, MA are looking for volunteers for an NIH-funded research study involving schizophrenia and marijuana use.

We are studying whether an FDA-approved drug, clozapine, can reduce marijuana use in individuals who suffer from schizophrenia and ongoing marijuana use.

Inclusion Criteria
- Age 18-55
- Suffers from schizophrenia or schizoaffective disorder
- Meets diagnostic criteria for marijuana abuse or dependence.

Exclusion Criteria:
- Suffers from any substance abuse disorder other than caffeine, nicotine, and alcohol abuse disorder
- Currently receives treatment with clozapine or risperidone, or suffers from a medical condition in which treatment with clozapine or risperidone would be impractical or unsafe

People in the study will be compensated for their time.

All information is kept private.

If you are interested and would like more information, please call Radhika Natarajan at 508-856-8323 or email: Radhika.Natarajan@umassmed.edu.

UMass Docket # H-00001171
Study #2: Study on Alcohol Abuse and Schizophrenia

The Psychotic Disorders Research Program at UMass Medical School in Worcester, MA is running an NIH-funded study to investigate whether the combination of risperidone and desipramine is effective in reducing alcohol consumption in individuals suffering from schizophrenia and ongoing alcohol drinking. Below are the major inclusion and exclusion criteria:

**Inclusion criteria**
- Age 18-65
- Suffers from schizophrenia or schizoaffective disorder
- Meets diagnostic criteria for current alcohol abuse or dependence

**Exclusion Criteria**
- Suffers from any substance abuse disorder other than caffeine, nicotine, and cannabinoid containing substances
- Continues to use alcohol despite treatment with medications such as naltrexone, acamprosate, disulfiram, topiramate, etc.

People in the study will be compensated for their time.

All information is kept private.

For more information contact Matthew Goodnow at 508-856-2494 or email: Matthew.Goodnow@umassmed.edu.

UMass Docket # H-14857
**Study #3: Study on Salsalate as an Adjunctive Treatment in Schizophrenia**

The Psychotic Disorders Research Program at UMass Medical School in Worcester, MA is currently running an NIH-funded study entitled *Salsalate as an Adjunctive Treatment in Patients with Schizophrenia.*

This is an open-label 12-week pilot research study examining how salsalate, an anti-inflammatory drug, affects positive and negative symptoms of schizophrenia, Hemoglobin A1c, fasting glucose, other metabolic issues and cognitive functioning when added to an antipsychotic medication. We are seeking your help to recruit eligible subjects.

**Inclusion Criteria**
- Age 18-65
- Diagnosis of schizophrenia or schizoaffective disorder
- Currently on a stable dose of antipsychotic medication (for at least one month)

**Exclusion Criteria**
- Current substance abuse
- Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary or thyroid diseases.
- Currently on immunosuppressant medication including oral steroids.
- Use of anti-coagulants

Subjects will be compensated for their time.

If you would like more information, please contact the Research Coordinator, Radhika Natarajan, at 508-856-8323 or via e-mail at Radhika.Natarajan@umassmed.edu.

UMass Docket # H-14814